Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Biotechnology

Healthcare
$95.05 +0.77%

+$0.42 today

Market cap
$7.47B
Beta
0.12
P/E (TTM)
57.2
EPS (TTM)
$0.95
52W Low $26.27High $59.87

Volume 0.33M

Average 0.66M

KNSA Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin narrows to 11.2%

Operating margin was 11.2% in Q2 FY2026, down 1.7 pp from a year earlier. On a trailing-twelve-month basis it was 11.9%, up 11.1 pp year over year. Over 3 fiscal years it widened by 7.0 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 5 analysts of 15.1% for the fiscal year ending Dec 2026, up from 11.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
11.2%-2.5 pp QoQ
Last fiscal yearDec 2025
11.4%+22.2 pp YoY
LTMJun 2026
11.9%+11.1 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.7 pp+3.2 pp+4.9 pp
1 year+22.2 pp+3.7 pp-18.4 pp
3 years+7.0 pp+5.2 pp-1.8 pp
5 years+27.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
11.4%
Year-over-year change
+22.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How KNSA compares with its peers on the latest reported figures

  • KNSA's LTM Jun 2026 operating margin of 11.9% is the 3rd highest of the 9 companies compared; the peer median is -619.2%.
  • Its year-over-year change of +11.1 pp is the 3rd highest of 7, against a peer median of -81.1 pp.
  • Over three fiscal years its change of +7.0 pp compares with a peer median of -338.6 pp.
KNSA Competitors Peer median
Operating Margin for KNSA and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202641.3% +360.6 pp+135.8 pp
ANABAnaptysBio, Inc.LTM Mar 202617.6% +107.2 pp+1139.8 pp
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 202611.9% +11.1 pp+7.0 pp
PHARPharming Group N.V.LTM Mar 20266.3% +6.1 pp-3.3 pp
SYRESpyre Therapeutics, Inc.LTM Sep 2026-276.5% ——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-961.9% -168.3 pp-673.9 pp
IMVTImmunovant, Inc.LTM Sep 2026-7488.4% ——
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-11441.4% -8764.8 pp-8276.4 pp
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-134164.4% -122732.2 pp-123394.3 pp
ORKAOruka Therapeutics, Inc.FY2025— ——
Peer median (excluding KNSA) -619.2%-81.1 pp-338.6 pp

Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.54M220.18M270.26M423.24M677.56M
Cost of Revenue9.1M22.9M56.52M60.91M307.41M
Gross Profit29.44M197.29M213.74M362.33M370.15M
Gross Margin76.4%89.6%79.1%85.6%54.6%
Research & Development99.3M65.49M76.1M111.62M96.85M
Selling, General & Admin85.95M97.95M129.43M168.01M196.27M
Operating Expenses186.08M187.51M238.93M407.95M292.93M
Depreciation & Amortization2.36M2.4M2.34M1.7M1.55M
EBITDA(154.18M)13.43M(14.31M)(34.46M)90.42M
EBITDA Margin-400.0%6.1%-5.3%-8.1%13.3%
Operating Income(156.64M)9.77M(25.2M)(45.62M)77.22M
Operating Margin-406.4%4.4%-9.3%-10.8%11.4%
Interest Income97K1.25M8.54M9.46M11.65M
Interest Expense00000
Other Income / Expenses97K1.25M8.54M9.46M11.65M
Income Before Tax(156.54M)11.03M(16.65M)(36.15M)88.87M
Pre-Tax Margin-406.1%5.0%-6.2%-8.5%13.1%
Income Tax Expense1.39M(172.34M)(30.74M)7.04M29.86M
Net Income(157.92M)183.36M14.08M(43.19M)59.01M
Net Margin-409.7%83.3%5.2%-10.2%8.7%
EPS (Basic)(2.30)2.640.20(0.60)0.80
EPS (Diluted)(2.30)2.600.20(0.60)0.75
Weighted Avg Shares68.58M69.38M70.06M71.42M74.2M
Weighted Avg Shares (Diluted)68.58M70.42M71.92M71.42M78.98M

Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Intrinsic Alpha fair value

Locked

Current Price

$95.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.